At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
duvoglustat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease
In Brief
A Phase 2 clinical trial evaluating duvoglustat and rhGAA for Pompe Disease. Completed, enrolled 25 participants across 15 sites in 4 countries.
Detailed Summary
This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPompe Disease
CountriesCanada, France, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartOct 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedJun 27, 2011
Enrollment StartOct 31, 2011
Primary CompletionJan 4, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.0 years ago
Interventions
duvoglustatdrug
Single oral dose
rhGAAdrug
Single intravenous infusion